Massachusetts General Hospital is the original and largest teaching hospital of Harvard Medical School located in the West End neighborhood of Boston, Massachusetts. It is the third oldest general hospital in the United States and has a capacity of 999 beds.

There are 999 beds in Harvard (Massachusetts Gen Hosp).

During the past decade, Harvard (Massachusetts Gen Hosp) conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 5 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Harvard (Massachusetts Gen Hosp)" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 39 trials, followed by "AIDS Clinical Trials Group" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "NYU Langone Health" with 2 trials sponsored and "Salubris Biotherapeutics Inc" with 2 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Harvard (Massachusetts Gen Hosp)" #1 collaborator was "Bristol-Myers Squibb" with 7 trials as a collaborator, "Glaxo Wellcome" with 5 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 4 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 3 trials as a collaborator and "University of Pennsylvania" with 3 trials as a collaborator. Other collaborators include 51 different institutions and companies that were collaborators in the rest 44 trials.

According to Clinical.Site data, the most researched conditions in "Harvard (Massachusetts Gen Hosp)" are "HIV Infections" (48 trials), "Corticobasal Degeneration (CBD)" (2 trials), "Corticobasal Syndrome (CBS)" (2 trials), "Cytomegalovirus Infections" (2 trials) and "Lipodystrophy" (2 trials). Many other conditions were trialed in "Harvard (Massachusetts Gen Hosp)" in a lesser frequency.

Most popular intervention types in "Harvard (Massachusetts Gen Hosp)" are "Drug" (51 trials), "Other" (5 trials), "Procedure" (2 trials), "Behavioral" (1 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Zidovudine" (18 trials), "Didanosine" (12 trials), "Indinavir sulfate" (8 trials), "Lamivudine" (7 trials) and "Stavudine" (7 trials). Other intervention names were less common.

The vast majority of trials in "Harvard (Massachusetts Gen Hosp)" are 66 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Harvard (Massachusetts Gen Hosp)". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 56 completed trials in Harvard (Massachusetts Gen Hosp), undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Harvard (Massachusetts Gen Hosp), 7 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 6 trials that are defined as “Not Applicable".